Heart Failure With Reduced Ejection Fraction Is Associated With Greater Cardiovascular Risk Following Lumbar Interbody Fusion Authors: Shankar S Thiru, Haseeb E Goheer, Calvin J Harris, Abdulrahman Nazif, Mina Botros, Jonathan J Carmouche Published: 2026 ABSTRACT AbstractStudy DesignRetrospective cohort study.ObjectiveTo compare perioperative cardiovascular outcomes between patients with heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF) following transforaminal or posterior lumbar interbody fusion (TLIF/PLIF).MethodsThe TriNetX Research Network was used to identify patients undergoing elective TLIF or PLIF between 2011 and 2025. Cohorts were defined by heart failure phenotype and propensity score–matched (PSM) 1:1 for baseline demographics and comorbidities. Outcomes included postoperative atrial fibrillation or flutter (AF/AFL), myocardial infarction (MI), and secondary complications within 90 days. Odds ratios with 95% confidence intervals were calculated. Significance was defined as p < 0.05.ResultsOf 46,431 patients, 1,253 (2.7%) had HFrEF, 1,920 (4.1%) had HFpEF, and 43,258 (93.2%) had no heart failure. After PSM, both phenotypes carried elevated risk relative to non-HF controls across measured complications, including acute respiratory failure, pneumonia, AF/AFL, acute kidney injury, venous thromboembolism, and 90-day emergency department visits (all p<0.05). In the direct phenotype comparison (1,217 matched pairs), acute MI occurred more frequently in HFrEF than HFpEF patients (14.4% vs. 8.7%, p<0.001). HFrEF was associated with greater odds of acute MI (OR 1.760 [95% CI: 1.363, 2.273], p<0.001) and AF/AFL (OR 1.278 [95% CI: 1.079, 1.513], p=0.005) compared with HFpEF.ConclusionAmong patients with heart failure undergoing TLIF or PLIF, those with HFrEF are at increased risk of postoperative AF/AFL and MI compared with HFpEF patients. These findings highlight the importance of distinguishing heart failure phenotype during preoperative risk stratification and may support enhanced perioperative precautions.Keywords: Spine, Heart failure, Complications, Lumbar spine Introduction Heart failure (HF) affects 7.4 million adults in the United States and accounted for 45% of cardiovascular deaths in 2022, with projections estimating a prevalence of 11.4 million by 2050.1,2 The burden is concentrated in older adults, among whom the risk of developing HF is approximately 20-fold higher and the prevalence reaches 8.9%. 1 Given that the US population over age 65 is projected to grow 42% by 2050, and that age is an independent risk factor for both lumbar degeneration and HF,3,4 spine surgeons will increasingly encounter HF as a comorbidity in candidates for elective fusion. The perioperative implications of HF are substantial. The 2024 AHA/ACC guidelines for perioperative cardiovascular management report that patients with HF face an approximately three times greater risk of perioperative mortality than patients with coronary artery disease alone. 5 In noncardiac surgery, including spine surgery, a preoperative diagnosis of HF has been associated with increased rates of atrial fibrillation and atrial flutter, myocardial infarction, renal failure, prolonged mechanical ventilation, cardiac arrest, and readmission.6-15 Despite this, widely used preoperative risk calculators, including the Revised Cardiac Risk Index (RCRI) and the ACS NSQIP Surgical Risk Calculator, treat heart failure as a binary variable and do not differentiate between HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). This distinction is not trivial: Huang and colleagues previously demonstrated that across a broad range of noncardiac procedures, HFrEF was associated with higher in-hospital mortality and 30-day readmission than HFpEF. 7 Whether a comparable phenotypic difference exists for patients undergoing transforaminal or posterior lumbar interbody fusion (TLIF/PLIF) has not been established. Therefore, the aim of this study was to compare perioperative cardiovascular outcomes between patients with HFrEF and HFpEF undergoing elective TLIF or PLIF, and to determine whether HF phenotype meaningfully alters perioperative risk in this population. Materials and Methods Study design and data sources This was a retrospective cohort study of patients from the TriNetX Research Network (TriNetX, LLC., Cambridge, MA, US). The TriNetX Research Network (TriNetX) is a research program that provides aggregated and de-identified electronic health record data from over 140 million patients across more than 110 healthcare organizations across North America and Western Europe. TriNetX enables researchers to query data using International Classification of Diseases (ICD) and Current Procedural Terminology (CPT) codes. Data displayed on the TriNetX platform are in aggregate form and only contain de-identified data. Thus, Institutional Review Board (IRB) approval was not required as our institution’s IRB considers study designs that use TriNetX to meet criteria for “Not Human Subjects” research. Study population & outcomes of interest Data from January 2011 to December 2025 were retrospectively reviewed to identify patients aged 18 to 89 years who underwent transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fusion (PLIF) procedures. Patients undergoing TLIF or PLIF procedures were identified using posterior or posterolateral procedure CPT code (22612, 22630, 22632, 226633, 22634) and an instrumentation code (22840, 22842, 22843, 22844, 22853). Patients were required to have continuous dataset enrollment from at least 90 days before to at least 90 days after their surgical procedure. Patients undergoing an emergent, concurrent, or revision procedure were excluded. Procedures with a combined approach, non-contiguous spinal involvement, or procedures secondary to infection, trauma, or malignancy were identified and excluded. Patients with missing demographic data, including age, height, weight, and sex, were also excluded. Patients were stratified into three cohorts based on preoperative heart failure history: heart failure with reduced ejection fraction (HFrEF), heart failure preserved ejection fraction (HFpEF), and non-heart failure. Patient Variables and Outcomes Relevant patient variables from TriNetX were collected, including demographic factors, comorbidities, and postoperative outcomes within the first 90 days (Supplemental Table 1). Patient demographic and clinical data collected included age, body mass index (BMI), sex, race and ethnicity, hypertension, chronic ischemic heart disease, diabetes mellitus, obstructive sleep apnea, and chronic kidney disease, nonrheumatic mitral valve disorder, nonrheumatic aortic valve disorder, nonrheumatic tricuspid valve disorder, nonrheumatic pulmonary valve disorder, history of endocarditis, and preoperative hemoglobin A1c. Outcomes of interest in this study were defined to include medical complications and emergency department utilization within ninety days following the index procedure. Medical complications included acute respiratory failure, pneumonia, acute myocardial infarction (MI), atrial fibrillation and flutter (Afib/flutter), acute on chronic heart failure, acute kidney failure, and venous embolism and thrombosis, Additionally, healthcare utilization was assessed using 90-day emergency department visits. Propensity-score Matching To mitigate bias, a 1:1 propensity score matching (PSM) algorithm using greedy nearest-neighbor matching without replacement and a caliper width of 0.01 was applied to balance covariates between each cohort comparison. Propensity scores were derived from logistic regression incorporating clinically relevant covariates: age, sex, race, body mass index, chronic ischemic heart disease, hypertension, obstructive sleep apnea, chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney disease, preoperative beta blocker usage, and hemoglobin A1c. Covariate balance was assessed using standardized mean differences (SMDs), with an SMD < 0.1 defined to indicate appropriate balance. Statistical Analysis Statistically significant differences in variables across the cohorts were assessed using Student t-tests for continuous variables and chi-square or Fisher exact tests for categorical variables. Odds ratios were calculated with 95% confidence intervals (CI) to quantify the association between heart failure phenotype and postoperative outcomes. Significance was defined as p < 0.05. Statistical analyses were conducted in R (R, version 4.5.2, Vienna, Austria) and the analytical tools available within the TriNetX platform. Results Cohort Characteristics Between January 2011 and December 2025, 46,431 patients who underwent a TLIF or PLIF procedure were identified. Of these, 1,253 (2.7%) had HFrEF, 1,920 patients (4.1%) had HFpEF, and 43,258 (93.2%) had no documented history of heart failure. Baseline demographic and clinical characteristics are summarized in Table 1. Patients with HFpEF or HFrEF were older than those without heart failure. The mean age was 69.6 ± 9.7 years in the HFrEF cohort, 80.9 ± 8.8 years in the HFpEF cohort, and 60.8 ± 12.9 years in the non-HF cohort. Female patients represented 38.5% of the HFrEF cohort, 52.8% of the HFpEF cohort, and 54.8% of the non-HF cohort. Across cohorts, the majority of patients were White (81.0%, 80.6%, and 82.3%, respectively). Hypertension, chronic ischemic heart disease, diabetes mellitus, CKD, and OSA were more prevalent among patients in the heart failure cohorts compared with those without heart failure. Table 1.Baseline demographics variables and comorbidities in patients​HFrEF n = 1,253HFpEF n = 1,920Non-HF n = 43,258Age (mean ± SD)69.6 (±9.7)70.9 (±8.8)60.8 (±12.9)Body Mass Index kg/m2 (mean ± SD)31.4 (±6.2)32.6 (±6.7)30.7 (±6.3)Gender Female38.5%52.8%54.8% Male61.5%47.2%45.2%Race White81.0%80.6%82.3% Black14.9%14.4%8.7% Asian0.9%1.2%1.7% Other or Unknown3.2%4.8%7.3%Hypertension88.9%92.2%46.1%Chronic Ischemic Heart Disease61.1%53.5%10.0%Diabetes Mellitus47.5%47.3%17.6%Obstructive Sleep Apnea34.9%38.4%10.8%Chronic Kidney Disease31.8%33.4%5.2%Long Term Anticoagulant Use35.6%32.1%4.8%Chronic Obstructive Pulmonary Disease23.1%27.7%5.2%Nonrheumatic Mitral Valve Disorder21.1%22.4%2.5%Nonrheumatic Aortic Valve Disorder15.9%19.9%1.8%Nonrheumatic Tricuspid Valve Disorder9.3%10.1%1.1%Nonrheumatic Pulmonary Valve Disorder3.1%3.3%0.3%History of Endocarditis2.6%2.2%0.2%Preoperative Hemoglobin A1c6.2 (±1.1)6.3 (±1.2)6.1 (±1.1)HFpEF, Heart failure preserved ejection fraction; HFrEF, heart failure reduced ejection fraction; HF, heart failure. Baseline demographics variables and comorbidities in patients HFpEF, Heart failure preserved ejection fraction; HFrEF, heart failure reduced ejection fraction; HF, heart failure. Propensity-score Matching Propensity score matching was performed to adjust for baseline differences between cohorts. After matching, 1,179 HFrEF patients were matched to 1,179 non-HF patients, 1,449 HFpEF patients were matched to 1,449 non-HF patients, and 1,217 HFRF patients were matched to 1,217 HFpEF patients. Covariate balance was achieved for the majority of demographic and clinical variables following matching, with standardized mean differences below the predefined threshold of 0.1 (Supplemental Table 1). Heart Failure Reduced Ejection Fraction Versus Non-Heart Failure 90-day Complications Compared with matched patients without HF, those with HFrEF demonstrated significantly higher rates of acute respiratory failure (11.9% vs 2.6%; p <0.001), pneumonia (6.0% vs. 1.1%; p <0.001), Afib/flutter (35.6% vs. 12.4%; p <0.001), acute kidney failure (17.6% vs. 6.5%; p <0.001), and venous embolism and thrombosis (4.0% vs. 2.0%; p = 0.046) (Table 2). Additionally, emergency department utilization within 90 days occurred in 23.7% of HFrEF patients compared with 9.5% of matched non-HF patients (p <0.001). HFrEF patients had significantly increased odds of acute respiratory failure (OR 4.990, 95% CI 3.352-7.429; p < 0 .001), pneumonia (OR 5.747, 95% CI 3.164-10.441; p < 0.001), AF/AFL (OR 3.915, 95% CI 3.173-4.832; p < 0.001), acute kidney failure (OR 3.066, 95% CI 2.328-4.037; p < 0.001), venous embolism (OR 1.998, 95% CI 1.214-3.289; p=0.006), and emergency department utilization (OR 2.967, 95% CI 2.342-3.759; p <0.001) compared with matched non-HF patients. Table 2.Complications after propensity-score matching heart failure reduced ejection fraction and non-heart failure cohorts​HFrEF n = 1,179Non-HF n = 1,179pAcute Respiratory Failure11.9%2.6% <0.001 Pneumonia6.0%1.1% <0.001 Acute Myocardial Infarction<10<10-Atrial Fibrillation and Flutter35.6%12.4% <0.001 Acute on Chronic Heart Failure16.3%--Acute Kidney Failure17.6%6.5% <0.001 Venous Embolism and Thrombosis4.0%2.0% 0.046 Emergency Department Visits23.7%9.5% <0.001 HFrEF, Heart failure preserved ejection fraction; HF, heart failure. Values are bolded for p < 0.05. Complications after propensity-score matching heart failure reduced ejection fraction and non-heart failure cohorts HFrEF, Heart failure preserved ejection fraction; HF, heart failure. Values are bolded for p < 0.05. Heart Failure Preserved Ejection Fraction Versus Non-Heart Failure 90-day Complications Postoperative complications when comparing HFpEF patients with non-HF controls are summarized in Table 3. HFpEF patients had higher rates of acute respiratory failure (11.8% vs. 2.5%; p <0.001), pneumonia (7.4% vs 1.4%; p <0.001), acute MI (7.5% vs 0.9%), Afib/flutter (29.6% vs. 9.5%; p <0.001), acute kidney failure (18.0% vs 6.4%; p <0.001), and venous embolism and thrombosis (4.0% vs 1.8%; p <0.001) when compared to non-HF patients. Emergency department utilization rates within 90 days were also significantly higher among HFpEF patients (23.9% vs 10.4%; p <0.001). Table 3.Complications after propensity-score matching heart failure preserved ejection fraction and non-heart failure cohorts​HFpEF n = 1,449Non-HF n = 1,449pAcute Respiratory Failure11.8%2.5% <0.001 Pneumonia7.4%1.4% <0.001 Acute Myocardial Infarction7.5%0.9% <0.001 Atrial Fibrillation and Flutter29.6%9.5% <0.001 Acute on Chronic Heart Failure18.0%0.0% <0.001 Acute Kidney Failure18.0%6.4% <0.001 Venous Embolism and Thrombosis4.0%1.8% <0.001 Emergency Department Visits23.9%10.4% <0.001 HFpEF, Heart failure preserved ejection fraction; HF, heart failure. Values are bolded for p < 0.05. Complications after propensity-score matching heart failure preserved ejection fraction and non-heart failure cohorts HFpEF, Heart failure preserved ejection fraction; HF, heart failure. Values are bolded for p < 0.05. Heart Failure Type Comparison of 90-day Complications When comparing HFrEF and HFpEF patients directly after PSM, only acute MI occurred at significantly higher rate in HFrEF patients compared to HFpEF patients (14.4% vs. 8.7%; p <0.001) (Table 4). Additionally, HFrEF patients had significantly greater odds of acute MI (OR 1.760, 95% CI 1.363-2.273; p = 0.005) and atrial fibrillation or flutter (OR 1.278, 95% CI 1.079-1.513; p = 0.005) (Table 5). Table 4.Complications after propensity-score matching heart failure reduced ejection fraction and heart failure preserved ejection fraction cohorts​HFrEF n = 1,217HFpEF n = 1,217pAcute Respiratory Failure12.1%10.8%0.859Pneumonia6.0%6.9%0.180Acute Myocardial Infarction14.4%8.7%<0.001Atrial Fibrillation and Flutter35.9%30.5%0.481Acute on Chronic Heart Failure16.9%13.6%0.447Acute Kidney Failure18.4%18.4%0.570Venous Embolism and Thrombosis3.9%4.2%0.673Emergency Department Visits24.5%25.3%0.806HFREF, heart failure reduced ejection fraction; HFPEF, heart failure preserved ejection fraction. Complications after propensity-score matching heart failure reduced ejection fraction and heart failure preserved ejection fraction cohorts HFREF, heart failure reduced ejection fraction; HFPEF, heart failure preserved ejection fraction. Table 5.Odds ratios after propensity score matching stratified by comparison​HFrEF vs. Non-HFHFpEF vs. Non-HFHFrEF vs. HFpEFAcute Respiratory Failure4.990 (3.352,7.429); p < 0.0015.229 (3.804,7.189); p < 0.0011.139 (0.887,1.463); p = 0.308Pneumonia5.747 (3.164,10.441); p <0.0015.818 (3.811,8.882); p <0.0010.861 (0.622,1.19); p 0.364Acute Myocardial Infarction-8.503 (5.186,13.942); p < 0.0011.760 (1.363,2.273); p <0.001Atrial Fibrillation and Flutter3.915 (3.173,4.832); p <0.0014.012 (3.346,4.81); p <0.0011.278 (1.079,1.513); p = 0.005Acute on Chronic Heart Failure--1.299 (1.04,1.622); p = 0.021Acute Kidney Failure3.066 (2.328,4.037); p <0.0013.228 (2.598,4.012); p < 0.0011.000 (0.815,1.228); p = 1.000Venous Embolism and Thrombosis1.998 (1.214,3.289); p = 0.0062.286 (1.518,3.443); p <0.0010.939 (0.628,1.404); p = 0.758Emergency Department Visits2.967 (2.342,3.759); p <0.0012.717 (2.269,3.254); p <0.0010.957 (0.796,1.150); p=0.639HFrEF, Heart failure reduced ejection fraction; HFpEF, Heart failure preserved ejection fraction; HF, heart failure. Odds ratios after propensity score matching stratified by comparison HFrEF, Heart failure reduced ejection fraction; HFpEF, Heart failure preserved ejection fraction; HF, heart failure. Discussion This study demonstrates that among patients with heart failure undergoing posterior or transforaminal lumbar interbody fusion (PLIF/TLIF), the distinction between reduced and preserved ejection fraction carries meaningful prognostic weight for specific cardiovascular complications. After propensity score matching, patients with heart failure with reduced ejection fraction (HFrEF) had significantly higher odds of acute myocardial infarction (OR 1.760, 95% CI: 1.363-2.273, p<0.001) and atrial fibrillation/atrial flutter (OR 1.278, 95% CI: 1.079-1.513, p=0.005) compared with patients with heart failure with preserved ejection fraction (HFpEF). When each heart failure phenotype was compared against non-heart failure controls, both cohorts demonstrated markedly elevated risk across all measured complications, with odds ratios ranging from three-to eight-fold for respiratory failure, pneumonia, myocardial infarction, atrial fibrillation/atrial flutter, acute kidney injury, venous thromboembolism, and emergency department visits. Heart failure as a perioperative risk factor in noncardiac surgery is well established. The 2024 AHA/ACC guidelines for perioperative cardiovascular management emphasize that patients with heart failure have an approximately three times greater risk for perioperative death than patients with coronary artery disease alone. 11 Within the spine surgery literature, Ahmad and colleagues previously demonstrated increased complication rates in spine fusion patients with cardiac disease but did not differentiate by heart failure phenotype. 5 The present study extends this work by providing phenotype-specific risk stratification in the setting of lumbar interbody fusion. Huang et al examined HFpEF versus HFrEF across a broad range of noncardiac surgical procedures and reported that HFrEF was associated with worse outcomes, including higher in-hospital mortality (OR 1.27) and increased 30-day readmission (OR 1.08). 10 Our findings are concordant with these results and refine them for the spine fusion population, specifically with respect to myocardial infarction and atrial arrhythmia risk. Importantly, current preoperative risk calculators, including the Revised Cardiac Risk Index (RCRI) and the ACS NSQIP Surgical Risk Calculator, do not distinguish heart failure phenotype. 16 The present data provide evidence that phenotype-specific stratification is clinically meaningful, at least with respect to ischemic and arrhythmic endpoints, and suggest that a binary classification of heart failure may be insufficient for optimal perioperative risk assessment in patients undergoing lumbar interbody fusion. Several pathophysiologic mechanisms may account for the differential cardiovascular risk observed between phenotypes. The increased myocardial infarction risk in HFrEF likely reflects reduced cardiac output and diminished coronary perfusion reserve. 17 Perioperative hemodynamic stress from blood loss, fluid shifts, and prone positioning may precipitate demand ischemia on an already compromised myocardium. 18 In the perioperative setting, tachycardia shortens diastolic filling time and increases myocardial oxygen demand, while hypotension reduces coronary perfusion pressure, creating a supply-demand mismatch that is poorly tolerated in patients with reduced systolic function.15,17 The elevated atrial fibrillation/atrial flutter risk in HFrEF is attributable to ventricular dilation leading to atrial stretch, fibrosis, and structural remodeling. 19 Chronically elevated left atrial pressures result in atrial scarring, slowed conduction velocity, and shortened action potential duration, all of which promote reentry and perpetuation of arrhythmia. Perioperative sympathetic activation and catecholamine surges further lower the arrhythmia threshold. 20 The prevalence of structural atrial remodeling is higher in HFrEF than in HFpEF, providing a plausible mechanistic explanation for the observed phenotypic difference. 19 These findings have direct implications for surgical decision-making in the elective lumbar fusion population. As the spine fusion population continues to age and carries an increasing comorbidity burden, phenotype-specific risk stratification provides an additional lever for refining patient selection beyond age and frailty indices alone. For patients with HFrEF, the incremental cardiovascular risk demonstrated here may inform discussions around the timing and necessity of fusion, the threshold for offering decompression alone in appropriate candidates, and the suitability of ambulatory or short-stay pathways that are increasingly applied to lumbar fusion. Surgical approach may also warrant consideration: although our dataset could not differentiate by approach, the hemodynamic burden of prone positioning and the blood loss associated with posterior interbody techniques raise the question of whether anterior or lateral approaches might be preferable in selected HFrEF patients, a hypothesis that merits dedicated investigation. At the preoperative and perioperative level, these findings support querying ejection fraction status in addition to the presence of heart failure during the spine workup. The 2024 AHA/ACC guidelines do not recommend routine preoperative echocardiography in stable patients but acknowledge that physician judgment may be exercised when results are expected to alter management in high-risk patients undergoing high-risk procedures. 21 Patients with HFrEF in particular may benefit from preoperative cardiology co-management and continuation of guideline-directed medical therapy through the perioperative period. Postoperatively, a lower threshold for telemetry monitoring and troponin surveillance is reasonable in HFrEF patients, given that most perioperative myocardial injury is asymptomatic. Informed consent discussions should reflect the incremental cardiovascular risk associated with HFrEF relative to HFpEF, particularly with respect to myocardial infarction and arrhythmia.22,23 Limitations This study is not without limitations. The retrospective administrative database design using TriNetX relies on ICD and CPT coding, which introduces potential for misclassification of heart failure phenotype, underreporting of complications, and inability to verify actual ejection fraction values. Surgical variables that influence cardiovascular outcomes, including number of levels fused, operative time, estimated blood loss, and anesthesia type, could not be captured in this dataset. Propensity score matching reduces but does not eliminate confounding, and residual unmeasured confounders such as heart failure severity, medication adherence, and intraoperative management may persist. The available procedural coding did not permit reliable differentiation between open and minimally invasive TLIF/PLIF [22]. Additionally, there remains a lack of consensus regarding what constitutes MIS-TLIF compared with open or mini-open techniques [23]. Some post-match covariates remained imbalanced, including valvular disorders, anticoagulation use, and hypertension, which should be acknowledged transparently. Myocardial infarction data were suppressed in the HFrEF versus non-heart failure comparison due to TriNetX de-identification thresholds, limiting interpretation of that specific comparison. Finally, the 90-day outcome window may miss late complications and does not capture long-term mortality. Conclusion Among patients with heart failure undergoing TLIF or PLIF, those with HFrEF are at significantly increased risk of postoperative AF/AFL and MI compared with HFpEF patients. These findings highlight the importance of distinguishing heart failure phenotype during preoperative risk stratification and may support enhanced precaution in the perioperative setting. Supplemental Material Supplemental material - Heart Failure With Reduced Ejection Fraction Is Associated With Greater Cardiovascular Risk Following Lumbar Interbody Fusion Supplemental material for Heart Failure With Reduced Ejection Fraction Is Associated With Greater Cardiovascular Risk Following Lumbar Interbody Fusion by Shankar S. Thiru, Haseeb E. Goheer, Calvin J. Harris, Abdulrahman Nazif, Mina Botros, and Jonathan J. Carmouche in Global Spine Journal. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. IRB Statement: Institutional review board approval was not required since this study utilized de-identified data derived from a national healthcare dataset. Supplemental Material: Supplemental material for this article is available online. ORCID iDs Haseeb E. Goheer https://orcid.org/0000-0003-4004-0202 Mina Botros https://orcid.org/0000-0001-9799-6067 Jonathan J. Carmouche https://orcid.org/0000-0002-3473-5203 Consent to Participate Informed consent was not required given the national healthcare dataset does not allow for identification of patients. Data Availability Statement Data generated by the study is available upon request.* References Associated Data Supplementary Materials Supplemental material - Heart Failure With Reduced Ejection Fraction Is Associated With Greater Cardiovascular Risk Following Lumbar Interbody Fusion Supplemental material for Heart Failure With Reduced Ejection Fraction Is Associated With Greater Cardiovascular Risk Following Lumbar Interbody Fusion by Shankar S. Thiru, Haseeb E. Goheer, Calvin J. Harris, Abdulrahman Nazif, Mina Botros, and Jonathan J. Carmouche in Global Spine Journal. Data Availability Statement Data generated by the study is available upon request.*